AFP and hepatocellular carcinoma: Ramucirumab survival benefit for HCC patients with AFP ≥400 ng/ml was first observed in the prespecified subgroup of patients (AFP ≥400 ng/ml) in REACH, the first Phase 3 study of ramucirumab completed in patients with HCC.